Incorporating Stakeholder Input into Budget Impact Models to Compare Stem Cell Mobilization Strategies
Inger Jensen, Peter A. McSweeney(Mesoblast (United States)), Elsa Schwartz, R.J. Halbert, Sarah Naoshy(Sanofi (United States)), Zhang Xiao(Sanofi (United States)), A. Grosvenor, Sheikh Usman Iqbal, Denise Rossi(Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia)
Cited by 0
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
|The Lancet Oncology|2018|2.3k
KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma
|New England Journal of Medicine|2020|1.9k